# Magnesium Glycinate Insomnia Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/magnesium-glycinate-insomnia-randomized-trial-evidence-review
Category: evidence-review
Summary: Magnesium Glycinate Insomnia Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa
Last reviewed: 2026-07-09
Reviewed by: Migaku Evidence Review
# Magnesium Glycinate Insomnia Randomized Trial: What the Evidence Says

## Quick Answer

Magnesium Glycinate Insomnia Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Mechanisms of Magnesium in Sleep Disorders | narrative review | 3 | 2025-10-15 | 10.2147/NSS.S552646 |
| A ‘Standard of Care PLUS’ Model for Preterm Birth Prevention: Integrating Nutrient and Gene Variant Analysis with Targeted Interventions | preclinical study | 4 | 2026-02-28 | 10.3390/jpm16030134 |

## What The Sources Report

- Small sample size Short duration High Insomnia 11 Tunc et al 2023 938 279/659 81.1 / R ISI, ESS Elderly outpatient patients / / Hypomagnesemia is Associated with EDS Unknown if EDS leads to hypomagnesemia or vice versa. [He Caijun (2025); evidence level 3]
- Low levels were associated with a higher CRP concentration in patients with OSA. [He Caijun (2025); evidence level 3]
- As a result, a disproportionate burden of adverse outcomes falls in Medicaid-eligible populations specifically. [Stone Leslie P. (2026); evidence level 4]
- The consequences of preterm birth extend far beyond the neonatal period and are associated with increased neurodevelopmental and cardiometabolic morbidity later in life. [Stone Leslie P. (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For magnesium glycinate insomnia randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- He Caijun (2025). The Mechanisms of Magnesium in Sleep Disorders. DOI: 10.2147/NSS.S552646. PMCID: PMC12535714. PMID: 41116797. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12535714/
- Stone Leslie P. (2026). A ‘Standard of Care PLUS’ Model for Preterm Birth Prevention: Integrating Nutrient and Gene Variant Analysis with Targeted Interventions. DOI: 10.3390/jpm16030134. PMCID: PMC13027778. PMID: 41893003. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13027778/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.